Eric Jonasch, MD - Optimizing Long-Term Care With Guideline-Recommended Systemic Treatment Options for von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

"Sir John Kirwan" 22 min · 24 Sep 2026 · The Agenda

Why The All Blacks Need PATIENCE With Dave Rennie | Ross Karl 56 min · 24 Sep 2026 · DSPN -RUGBY

Family Flowers Only - Bonus Ep 22 min · 24 Sep 2026 · Family Flowers Only by Grief Ireland

INTERVIEW: The Traitors’ Josh Packham Spills BTS Filming Secrets, Unseen Drama, Alex’s Betrayal, Kirby’s Win & His Pre-Game Strategy With Twin Brother Luke | 679 1h 25m · 24 Sep 2026 · So Dramatic! with Megan Pustetto

Latrell's $1.7m Move, Roosters’ Finals Test & Knights Sniff An Upset | Kenty Blitz 32 min · 24 Sep 2026 · Kenty - Paul Kent NRL Podcast

NPR News: 09-23-2026 11PM EDT 5 min · 24 Sep 2026 · NPR News Now

Report any issue

Source

Recorded27 Jul 2023

Publisherc.answersincme.com ↗

Handlerec:766073

Show notes

Please visit answersincme.com/XJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and urology discuss guideline-recommended systemic treatment options and strategies to optimize long-term care for patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC). Upon completion of this activity, participants should be better able to: Recognize unmet needs in the management of VHL disease-associated RCC; Describe the clinical impact of current guideline-recommended systemic treatment options for VHL disease-associated RCC; and Identify strategies to optimize long-term care for patients with VHL disease-associated RCC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in